HOME > Business Wire > Article
JCR Pharmaceuticals to Present at the American Society of Gene and Cell Therapy 28th Annual Meeting
HYOGO, Japan--( BUSINESS WIRE )-- JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) announced today that it will present updated preclinical data from its proprietary J-Brain Cargo®-applied adeno-associated virus (AAV) vector gene therapy non-clinical research programs in an oral abstract session at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, being held May 13-17, 2025, in New Orleans, LA.
The oral presentation details are listed below, and the full program can be found on the ASGCT congress website at https://annualmeeting.asgct.org/ .
Title: Incorporation of transferrin receptor binder and surface mutations into AAV enables efficient brain delivery and reduced liver tropism
Session: AAV Gene Transfer (A): Crossing the Blood-Brain Barrier
Abstract Number: 92
Date/Time: Wednesday, May 14, 2:30-2:45pm CT
Presenter: Yuhei Ashida, Associate Senior Scientist, at JCR Pharmaceuticals
About the American Society of Gene and Cell Therapy (ASGCT)
The American Society of Gene and Cell Therapy (ASGCT) is the primary professional membership organization for gene and cell therapy. The Society's members are scientists, physicians, patient advocates, and other professionals. The mission of the ASGCT is to advance knowledge, awareness, and education, leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease. For more information, please visit
www
.asgct.org
.
About the J-Brain Cargo® Platform Technology
JCR Pharmaceuticals has developed a proprietary blood-brain barrier (BBB)-penetrating technology, J-Brain Cargo®, to bring biotherapeutics into the central nervous system (CNS). The first drug developed based on this technology is IZCARGO® (INN: pabinafusp alfa) and was approved in Japan for the treatment of a lysosomal storage disorder.
About JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients’ lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler- Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. For more information, please visit
https://www.jcrpharm.co.jp/en/site/en/
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250508730248/en/
Contacts
Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jp.jcrpharm.com
Source: JCR Pharmaceuticals Co., Ltd.
Business Wire
-
05/09 13:00 Full Immersion with Voice Acting & Bonus Story! Mystery Adventure ...
-
05/09 12:00 LogProstyle Announces Relocation of Corporate Headquarters and Grand O...
-
05/09 08:24 Nidec Announces the Withdrawal of the Tender Offer for Makino Milling ...
-
05/09 07:00 Kioxia Receives IEEE Corporate Innovation Award
-
05/09 04:48 AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. Announce Completion o...
-
05/09 03:00 Yamashita, Provider of Nursing Care Product Rentals, Launches Wholesal...
-
05/08 16:05 JCR Pharmaceuticals to Present at the American Society of Gene and Cel...
-
05/08 15:00 Yamaha Music Innovations Fund to Begin Investing in Startup Companies ...
-
05/08 11:23 Kaname Capital Submits Shareholder Proposals for the June 2025 Annual ...
-
05/08 07:48 Accenture to Acquire Yumemi to Accelerate the Launch of Innovative and...
-
05/08 06:36 Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflectin...
-
05/08 04:00 Gunze Apparel Business Establishes Sustainable Supply Chain
-
05/08 04:00 Toyoda Gosei Develops New Steering Wheel for Next-Generation Steering ...
-
05/08 02:00 Movie director Tetsuichiro Tsuta, a graduate of Tokyo Polytechnic Univ...
-
05/07 23:30 Palliser Recognizes Progress in Nomination Process for Independent Dir...
-
05/07 21:00 Marubeni and ExxonMobil’s Low-Carbon Ammonia Deal Marks Major Step i...
-
05/07 16:00 OKI to Exhibit Motion-tolerant FA Cables and FPCs at AUTOMATE 2025 in ...
-
05/07 15:31 Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis...
-
05/07 15:25 EUCALIA Inc. and Hippocratic AI Partner to Bring World’s First Non-D...
-
05/07 13:19 AVI Urges Wacom To Make Governance Changes
-
05/07 12:30 Crown Bioscience Achieves Green Lab Sustainability Certification
-
05/07 07:44 Oasis Urges Taiyo HD Shareholders to Vote Against the Re-election of M...
-
05/07 06:30 ENHERTU® Followed by THP Before Surgery Showed Statistically Signific...
-
05/07 04:03 ispace Completes Success 7 of Mission 2 Milestones
-
05/06 12:30 Coincheck Group N.V. to Announce Fourth Quarter 2025 Results on May 13...
-
05/06 12:30 Asahi Kasei Microdevices Launches New Series of Power Management ICs f...
-
05/06 10:30 Mokulele Airlines and Japan Airlines Announce New Interline Agreement
-
05/06 01:00 AGC Biologics Partners with Novelty Nobility for Cell Line Development...
-
05/05 12:49 Former Mitsubishi Heavy Industries Executive Yasushi Fukuizumi Joins Z...
-
05/05 02:00 Fueling the Race to Space Innovation: Join the 2025 RunSpace Innovatio...